For patients living with the most common genomic subtype of advanced lung cancer, a fundamental treatment question is sharpening: does everyone need more aggressive combination therapy, or can carefully selected patients still do well on a single targeted agent? The answer has significant implications not just for survival statistics but for quality of life during treatment.

Two landmark trials are reshaping first-line treatment of EGFR-mutated non-small cell lung cancer. The FLAURA2 trial demonstrated that adding platinum-pemetrexed chemotherapy to osimertinib extended median overall survival from 37.6 to 47.5 months — a nearly 10-month gain — with a hazard ratio for death of 0.77. The MARIPOSA trial produced a comparable survival signal by pairing the bispecific antibody amivantamab with the third-generation EGFR inhibitor lazertinib, achieving a hazard ratio of 0.75 versus osimertinib monotherapy, whose median overall survival in that comparison was 36.7 months. Both combinations statistically outperform osimertinib alone, yet both impose substantially higher toxicity burdens and treatment complexity compared to the oral, well-tolerated monotherapy standard.

What makes this analysis particularly important is its focus on a frequently overlooked clinical reality: roughly one-third of patients receiving first-line osimertinib monotherapy in clinical trials never access second-line therapy at all — whether due to disease progression, decline in performance status, or treatment-related complications. This observation fundamentally challenges the assumption that intensifying upfront treatment uniformly benefits all patients. In oncology broadly, survival gains on a population level can mask heterogeneous individual outcomes, and the patients who bear the highest toxicity burden may not be those deriving the largest survival benefit. Biomarker-driven patient selection — using tools like circulating tumor DNA or co-mutation profiling — will likely become essential for matching treatment intensity to individual risk. This is an incrementally confirmatory but clinically consequential analysis that appropriately challenges reflexive escalation toward combination regimens without individualized risk-benefit assessment.